EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMD

Go back to EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMD
(NASDAQ: EYPT) Delayed: 0.43 +0.02 (4.88%)
Previous Close $0.41    52 Week High $ 
Open $0.42    52 Week Low $ 
Day High $0.44    P/E N/A 
Day Low $0.39    EPS $ 
Volume 31,573,514